Download PDF
Semin Liver Dis 2010; 30(1): 075-086
DOI: 10.1055/s-0030-1247134
© Thieme Medical Publishers

Identification of Novel Oncogenes and Tumor Suppressors in Hepatocellular Carcinoma

Sandrine Imbeaud1 , 2 , Yannick Ladeiro1 , 2 , Jessica Zucman-Rossi1 , 2 , 3
  • 1Inserm, U674, Génomique Fonctionnelle des Tumeurs Solides, Paris, France
  • 2Université Paris Descartes, Paris, France
  • 3AP-HP, HEGP, Service d'oncologie médicale, Paris, France
Further Information

Publication History

Publication Date:
19 February 2010 (online)

    Permissions and Reprints

ABSTRACT

Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma (HCC) is challenging, both because of the tumor complexity and the difficulty in integrating the very large amount of data provided by different approaches. The authors consider it very important to identify new pathways of carcinogenesis and to understand the mechanisms underlying their alteration in tumors to design personalized treatments for HCC. In this review, the main global genomic approaches are considered in detail. The authors present a catalog of the most important oncogenes and tumor suppressor genes that have been found to be mutated in HCC and hepatocellular adenoma. They also review the results provided by transcriptome and miRNA profiling, in terms of molecular tumor classification. The authors anticipate that high-throughput sequencing will considerably refine the description of the genetic alterations in HCC. They also predict that systems biology, the recently developed interdisciplinary research field, will be very important to integrate the colossal amounts of data generated by the new technologies and to identify useful clinical applications.

KEYWORDS

Hepatocellular carcinoma - hepatocellular adenoma - oncogene - tumor suppressor gene - gene mutation - beta-catenin - TP53 - gp130 - Stat3 - MiRNA - genomic - transcriptome - benign tumor - malignant transformation

REFERENCES

  • 1 Parkin D M. Global cancer statistics in the year 2000.  Lancet Oncol. 2001;  2(9) 533-543
    CrossrefPubMedGoogle Scholar
  • 2 El-Serag H B. Hepatocellular carcinoma: recent trends in the United States.  Gastroenterology. 2004;  127(5, Suppl 1) S27-S34
    CrossrefPubMedGoogle Scholar
  • 3 McGlynn K A, London W T. Epidemiology and natural history of hepatocellular carcinoma.  Best Pract Res Clin Gastroenterol. 2005;  19(1) 3-23
    CrossrefPubMedGoogle Scholar
  • 4 Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening.  Semin Liver Dis. 2005;  25(2) 143-154
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Taylor-Robinson S D, Foster G R, Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94.  Lancet. 1997;  350(9085) 1142-1143
    PubMedGoogle Scholar
  • 6 Donato F, Gelatti U, Limina R M, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence.  Oncogene. 2006;  25(27) 3756-3770
    CrossrefPubMedGoogle Scholar
  • 7 Seeff L B, Hoofnagle J H. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity.  Oncogene. 2006;  25(27) 3771-3777
    CrossrefPubMedGoogle Scholar
  • 8 Bralet M P, Régimbeau J M, Pineau P et al.. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases.  Hepatology. 2000;  32(2) 200-204
    CrossrefPubMedGoogle Scholar
  • 9 Lee J S, Chu I S, Heo J et al.. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.  Hepatology. 2004;  40(3) 667-676
    CrossrefPubMedGoogle Scholar
  • 10 Lee J S, Heo J, Libbrecht L et al.. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.  Nat Med. 2006;  12(4) 410-416
    CrossrefPubMedGoogle Scholar
  • 11 Villanueva A, Newell P, Chiang D Y, Friedman S L, Llovet J M. Genomics and signaling pathways in hepatocellular carcinoma.  Semin Liver Dis. 2007;  27(1) 55-76
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Boyault S, Rickman D S, de Reyniès A et al.. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.  Hepatology. 2007;  45(1) 42-52
    CrossrefPubMedGoogle Scholar
  • 13 Cieply B, Zeng G, Proverbs-Singh T, Geller D A, Monga S P. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.  Hepatology. 2009;  49(3) 821-831
    CrossrefPubMedGoogle Scholar
  • 14 de La Coste A, Romagnolo B, Billuart P et al.. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.  Proc Natl Acad Sci U S A. 1998;  95(15) 8847-8851
    CrossrefPubMedGoogle Scholar
  • 15 Huang H, Fujii H, Sankila A et al.. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.  Am J Pathol. 1999;  155(6) 1795-1801
    PubMedGoogle Scholar
  • 16 Legoix P, Bluteau O, Bayer J et al.. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity.  Oncogene. 1999;  18(27) 4044-4046
    CrossrefPubMedGoogle Scholar
  • 17 Miyoshi Y, Iwao K, Nagasawa Y et al.. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3.  Cancer Res. 1998;  58(12) 2524-2527
    PubMedGoogle Scholar
  • 18 Taniguchi K, Roberts L R, Aderca I N et al.. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.  Oncogene. 2002;  21(31) 4863-4871
    CrossrefPubMedGoogle Scholar
  • 19 Terris B, Pineau P, Bregeaud L et al.. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas.  Oncogene. 1999;  18(47) 6583-6588
    CrossrefPubMedGoogle Scholar
  • 20 Wong C M, Fan S T, Ng I O. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance.  Cancer. 2001;  92(1) 136-145
    CrossrefPubMedGoogle Scholar
  • 21 Ishizaki Y, Ikeda S, Fujimori M et al.. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.  Int J Oncol. 2004;  24(5) 1077-1083
    PubMedGoogle Scholar
  • 22 Kim Y D, Park C H, Kim H S et al.. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.  J Gastroenterol Hepatol. 2008;  23(1) 110-118
    CrossrefPubMedGoogle Scholar
  • 23 Laurent-Puig P, Legoix P, Bluteau O et al.. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis.  Gastroenterology. 2001;  120(7) 1763-1773
    CrossrefPubMedGoogle Scholar
  • 24 Park J Y, Park W S, Nam S W et al.. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis.  Liver Int. 2005;  25(1) 70-76
    CrossrefPubMedGoogle Scholar
  • 25 Satoh S, Daigo Y, Furukawa Y et al.. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.  Nat Genet. 2000;  24(3) 245-250
    CrossrefPubMedGoogle Scholar
  • 26 Zucman-Rossi J, Benhamouche S, Godard C et al.. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.  Oncogene. 2007;  26(5) 774-780
    CrossrefPubMedGoogle Scholar
  • 27 Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.  , [see comments] Nature. 1991;  350(6317) 429-431
    CrossrefPubMedGoogle Scholar
  • 28 Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan.  Hepatology. 1995;  22(6) 1702-1707
    CrossrefPubMedGoogle Scholar
  • 29 Honda K, Sbisà E, Tullo A et al.. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.  Br J Cancer. 1998;  77(5) 776-782
    CrossrefPubMedGoogle Scholar
  • 30 Hussain S P, Schwank J, Staib F, Wang X W, Harris C C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.  Oncogene. 2007;  26(15) 2166-2176
    CrossrefPubMedGoogle Scholar
  • 31 Challen C, Guo K, Collier J D, Cavanagh D, Bassendine M F. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas.  J Hepatol. 1992;  14(2-3) 342-346
    CrossrefPubMedGoogle Scholar
  • 32 Leon M, Kew M C. Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks.  Anticancer Res. 1995;  15(3) 859-861
    PubMedGoogle Scholar
  • 33 Takada S, Koike K. Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells.  Oncogene. 1989;  4(2) 189-193
    PubMedGoogle Scholar
  • 34 Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma.  Jpn J Cancer Res. 1989;  80(3) 196-199
    CrossrefPubMedGoogle Scholar
  • 35 Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride.  Br J Cancer. 2001;  84(7) 982-989
    CrossrefPubMedGoogle Scholar
  • 36 Bluteau O, Jeannot E, Bioulac-Sage P et al.. Bi-allelic inactivation of TCF1 in hepatic adenomas.  Nat Genet. 2002;  32(2) 312-315
    CrossrefPubMedGoogle Scholar
  • 37 Rebouissou S, Amessou M, Couchy G et al.. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.  Nature. 2009;  457(7226) 200-204
    CrossrefPubMedGoogle Scholar
  • 38 Zhang X, Xu H J, Murakami Y et al.. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma.  Cancer Res. 1994;  54(15) 4177-4182
    PubMedGoogle Scholar
  • 39 Chen T C, Hsieh L L, Kuo T T et al.. p16INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma.  Anticancer Res. 2000;  20(3A, 3A) 1621-1626
    PubMedGoogle Scholar
  • 40 Kita R, Nishida N, Fukuda Y et al.. Infrequent alterations of the p16INK4A gene in liver cancer.  Int J Cancer. 1996;  67(2) 176-180
    CrossrefPubMedGoogle Scholar
  • 41 Liew C T, Li H M, Lo K W et al.. High frequency of p16INK4A gene alterations in hepatocellular carcinoma.  Oncogene. 1999;  18(3) 789-795
    CrossrefPubMedGoogle Scholar
  • 42 Lee J W, Soung Y H, Kim S Y et al.. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.  Oncogene. 2005;  24(8) 1477-1480
    CrossrefPubMedGoogle Scholar
  • 43 Tanaka Y, Kanai F, Tada M et al.. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.  Oncogene. 2006;  25(20) 2950-2952
    CrossrefPubMedGoogle Scholar
  • 44 Kawate S, Takenoshita S, Ohwada S et al.. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma.  Int J Oncol. 1999;  14(1) 127-131
    PubMedGoogle Scholar
  • 45 Yakicier M C, Irmak M B, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma.  Oncogene. 1999;  18(34) 4879-4883
    CrossrefPubMedGoogle Scholar
  • 46 Bae J J, Rho J W, Lee T J et al.. Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients.  Oncol Rep. 2007;  18(4) 1007-1013
    PubMedGoogle Scholar
  • 47 Fujiwara Y, Hoon D S, Yamada T et al.. PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas.  Jpn J Cancer Res. 2000;  91(3) 287-292
    PubMedGoogle Scholar
  • 48 Kawamura N, Nagai H, Bando K et al.. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors.  Jpn J Cancer Res. 1999;  90(4) 413-418
    PubMedGoogle Scholar
  • 49 Wang Y, Lee A T, Ma J Z et al.. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target.  J Biol Chem. 2008;  283(19) 13205-13215
    CrossrefPubMedGoogle Scholar
  • 50 Yao Y J, Ping X L, Zhang H et al.. PTEN/MMAC1 mutations in hepatocellular carcinomas.  Oncogene. 1999;  18(20) 3181-3185
    CrossrefPubMedGoogle Scholar
  • 51 De Souza A T, Hankins G R, Washington M K, Orton T C, Jirtle R L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity.  Nat Genet. 1995;  11(4) 447-449
    CrossrefPubMedGoogle Scholar
  • 52 Oka Y, Waterland R A, Killian J K et al.. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan.  Hepatology. 2002;  35(5) 1153-1163
    CrossrefPubMedGoogle Scholar
  • 53 Yamada T, De Souza A T, Finkelstein S, Jirtle R L. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis.  Proc Natl Acad Sci U S A. 1997;  94(19) 10351-10355
    CrossrefPubMedGoogle Scholar
  • 54 Park W S, Dong S M, Kim S Y et al.. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.  Cancer Res. 1999;  59(2) 307-310
    PubMedGoogle Scholar
  • 55 Yang D H, Huang W, Cui J et al.. The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma.  Hepatobiliary Pancreat Dis Int. 2004;  3(1) 86-89
    PubMedGoogle Scholar
  • 56 Kim C J, Cho Y G, Park J Y et al.. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas.  Eur J Cancer. 2004;  40(1) 136-141
    CrossrefPubMedGoogle Scholar
  • 57 Pelletier L, Rebouissou S, Paris A et al.. Loss of HNF1a function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis.  Hepatology. 2009;  51(2) 557-566
    CrossrefPubMedGoogle Scholar
  • 58 Zucman-Rossi J, Jeannot E, Nhieu J T et al.. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.  Hepatology. 2006;  43(3) 515-524
    CrossrefPubMedGoogle Scholar
  • 59 Bioulac-Sage P, Rebouissou S, Thomas C et al.. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.  Hepatology. 2007;  46(3) 740-748
    CrossrefPubMedGoogle Scholar
  • 60 Chen Y W, Jeng Y M, Yeh S H, Chen P J. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.  Hepatology. 2002;  36(4 Pt 1) 927-935
    PubMedGoogle Scholar
  • 61 Van der Borght S, Libbrecht L, Katoonizadeh A et al.. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy.  Histopathology. 2007;  51(6) 855-856
    CrossrefPubMedGoogle Scholar
  • 62 Cavard C, Colnot S, Audard V et al.. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology.  Future Oncol. 2008;  4(5) 647-660
    CrossrefPubMedGoogle Scholar
  • 63 Nagafuchi A, Takeichi M. Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin.  Cell Regul. 1989;  1(1) 37-44
    PubMedGoogle Scholar
  • 64 Micsenyi A, Tan X, Sneddon T, Luo J H, Michalopoulos G K, Monga S P. Beta-catenin is temporally regulated during normal liver development.  Gastroenterology. 2004;  126(4) 1134-1146
    CrossrefPubMedGoogle Scholar
  • 65 Suksaweang S, Lin C M, Jiang T X, Hughes M W, Widelitz R B, Chuong C M. Morphogenesis of chicken liver: identification of localized growth zones and the role of beta-catenin/Wnt in size regulation.  Dev Biol. 2004;  266(1) 109-122
    CrossrefPubMedGoogle Scholar
  • 66 Monga S P, Monga H K, Tan X, Mulé K, Pediaditakis P, Michalopoulos G K. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification.  Gastroenterology. 2003;  124(1) 202-216
    CrossrefPubMedGoogle Scholar
  • 67 Benhamouche S, Decaens T, Godard C et al.. Apc tumor suppressor gene is the “zonation-keeper” of mouse liver.  Dev Cell. 2006;  10(6) 759-770
    CrossrefPubMedGoogle Scholar
  • 68 Cadoret A, Ovejero C, Terris B et al.. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism.  Oncogene. 2002;  21(54) 8293-8301
    CrossrefPubMedGoogle Scholar
  • 69 Monga S P, Pediaditakis P, Mule K, Stolz D B, Michalopoulos G K. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration.  Hepatology. 2001;  33(5) 1098-1109
    CrossrefPubMedGoogle Scholar
  • 70 Tan X, Behari J, Cieply B, Michalopoulos G K, Monga S P. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration.  Gastroenterology. 2006;  131(5) 1561-1572
    CrossrefPubMedGoogle Scholar
  • 71 Audard V, Grimber G, Elie C et al.. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations.  J Pathol. 2007;  212(3) 345-352
    CrossrefPubMedGoogle Scholar
  • 72 Fujito T, Sasaki Y, Iwao K et al.. Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma.  Hepatogastroenterology. 2004;  51(58) 921-924
    PubMedGoogle Scholar
  • 73 Hsu H C, Jeng Y M, Mao T L, Chu J S, Lai P L, Peng S Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.  Am J Pathol. 2000;  157(3) 763-770
    CrossrefPubMedGoogle Scholar
  • 74 Chiang D Y, Villanueva A, Hoshida Y et al.. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.  Cancer Res. 2008;  68(16) 6779-6788
    CrossrefPubMedGoogle Scholar
  • 75 Ovejero C, Cavard C, Périanin A et al.. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver.  Hepatology. 2004;  40(1) 167-176
    CrossrefPubMedGoogle Scholar
  • 76 Lieu H T, Batteux F, Simon M T et al.. HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice.  Hepatology. 2005;  42(3) 618-626
    CrossrefPubMedGoogle Scholar
  • 77 Renard C A, Labalette C, Armengol C et al.. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.  Cancer Res. 2007;  67(3) 901-910
    CrossrefPubMedGoogle Scholar
  • 78 Yamashita T, Ji J, Budhu A et al.. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.  Gastroenterology. 2009;  136(3) 1012-1024
    CrossrefPubMedGoogle Scholar
  • 79 Baum J K, Bookstein J J, Holtz F, Klein E W. Possible association between benign hepatomas and oral contraceptives.  Lancet. 1973;  2(7835) 926-929
    Google Scholar
  • 80 Christopherson W M, Mays E T, Barrows G. A clinicopathologic study of steroid-related liver tumors.  Am J Surg Pathol. 1977;  1(1) 31-41
    CrossrefPubMedGoogle Scholar
  • 81 Edmondson H A, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives.  N Engl J Med. 1976;  294(9) 470-472
    CrossrefPubMedGoogle Scholar
  • 82 Lansing P B, McQuitty J T, Bradburn D M. Benign liver tumors: what is their relationship to oral contraceptives?.  Am Surg. 1976;  42(10) 744-760
    PubMedGoogle Scholar
  • 83 Rooks J B, Ory H W, Ishak K G et al.. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use.  JAMA. 1979;  242(7) 644-648
    CrossrefPubMedGoogle Scholar
  • 84 Vana J, Murphy G P, Aronoff B L, Baker H W. Primary liver tumors and oral contraceptives. Results of a survey.  JAMA. 1977;  238(20) 2154-2158
    CrossrefPubMedGoogle Scholar
  • 85 Kent D R, Nissen E D, Nissen S E, Ziehm D J. Effect of pregnancy on liver tumor associated with oral contraceptives.  Obstet Gynecol. 1978;  51(2) 148-151
    PubMedGoogle Scholar
  • 86 Kerlin P, Davis G L, McGill D B, Weiland L H, Adson M A, Sheedy II P F. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features.  Gastroenterology. 1983;  84(5 Pt 1) 994-1002
    PubMedGoogle Scholar
  • 87 Foster J H, Berman M M. The malignant transformation of liver cell adenomas.  Arch Surg. 1994;  129(7) 712-717
    PubMedGoogle Scholar
  • 88 Grigsby P, Meyer J S, Sicard G A, Huggins M B, Lamar D J, DeSchryver-Kecskemeti K. Hepatic adenoma within a spindle cell carcinoma in a woman with a long history of oral contraceptives.  J Surg Oncol. 1987;  35(3) 173-179
    CrossrefPubMedGoogle Scholar
  • 89 Gyorffy E J, Bredfeldt J E, Black W C. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use.  Ann Intern Med. 1989;  110(6) 489-490
    PubMedGoogle Scholar
  • 90 Korula J, Yellin A, Kanel G, Campofiori G, Nichols P. Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use.  West J Med. 1991;  155(4) 416-418
    PubMedGoogle Scholar
  • 91 Tao L C. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation.  Cancer. 1991;  68(2) 341-347
    CrossrefPubMedGoogle Scholar
  • 92 Bioulac-Sage P, Laumonier H, Couchy G et al.. Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience.  Hepatology. 2009;  50 481-489
    CrossrefPubMedGoogle Scholar
  • 93 Hsu I C, Metcalf R A, Sun T, Welsh J A, Wang N J, Harris C C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas.  Nature. 1991;  350(6317) 427-428
    CrossrefPubMedGoogle Scholar
  • 94 Sun C A, Wang L Y, Chen C J et al.. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan.  Carcinogenesis. 2001;  22(8) 1289-1294
    CrossrefPubMedGoogle Scholar
  • 95 Bluteau O, Beaudoin J-C, Pasturaud P et al.. Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping.  Oncogene. 2002;  21(8) 1225-1232
    CrossrefPubMedGoogle Scholar
  • 96 Hoshida Y, Nijman S M, Kobayashi M et al.. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.  Cancer Res. 2009;  69(18) 7385-7392
    CrossrefPubMedGoogle Scholar
  • 97 Chen X, Cheung S T, So S et al.. Gene expression patterns in human liver cancers.  Mol Biol Cell. 2002;  13(6) 1929-1939
    CrossrefPubMedGoogle Scholar
  • 98 Breuhahn K, Vreden S, Haddad R et al.. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression.  Cancer Res. 2004;  64(17) 6058-6064
    CrossrefPubMedGoogle Scholar
  • 99 Kaposi-Novak P, Lee J S, Gòmez-Quiroz L, Coulouarn C, Factor V M, Thorgeirsson S S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.  J Clin Invest. 2006;  116(6) 1582-1595
    CrossrefPubMedGoogle Scholar
  • 100 Coulouarn C, Factor V M, Thorgeirsson S S. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.  Hepatology. 2008;  47(6) 2059-2067
    CrossrefPubMedGoogle Scholar
  • 101 Yamashita T, Forgues M, Wang W et al.. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.  Cancer Res. 2008;  68(5) 1451-1461
    CrossrefPubMedGoogle Scholar
  • 102 Hoshida Y, Villanueva A, Kobayashi M et al.. Gene expression in fixed tissues and outcome in hepatocellular carcinoma.  N Engl J Med. 2008;  359(19) 1995-2004
    CrossrefPubMedGoogle Scholar
  • 103 Cullen B R. Transcription and processing of human microRNA precursors.  Mol Cell. 2004;  16(6) 861-865
    CrossrefPubMedGoogle Scholar
  • 104 Murakami Y, Yasuda T, Saigo K et al.. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.  Oncogene. 2006;  25(17) 2537-2545
    CrossrefPubMedGoogle Scholar
  • 105 Kutay H, Bai S, Datta J et al.. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas.  J Cell Biochem. 2006;  99(3) 671-678
    CrossrefPubMedGoogle Scholar
  • 106 Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob S T, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.  Gastroenterology. 2007;  133(2) 647-658
    CrossrefPubMedGoogle Scholar
  • 107 Gramantieri L, Ferracin M, Fornari F et al.. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.  Cancer Res. 2007;  67(13) 6092-6099
    CrossrefPubMedGoogle Scholar
  • 108 Huang Y S, Dai Y, Yu X F et al.. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis.  J Gastroenterol Hepatol. 2008;  23(1) 87-94
    CrossrefPubMedGoogle Scholar
  • 109 Jiang J, Gusev Y, Aderca I et al.. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.  Clin Cancer Res. 2008;  14(2) 419-427
    CrossrefPubMedGoogle Scholar
  • 110 Varnholt H, Drebber U, Schulze F et al.. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma.  Hepatology. 2008;  47(4) 1223-1232
    CrossrefPubMedGoogle Scholar
  • 111 Ladeiro Y, Couchy G, Balabaud C et al.. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.  Hepatology. 2008;  47(6) 1955-1963
    CrossrefPubMedGoogle Scholar
  • 112 Connolly E, Melegari M, Landgraf P et al.. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype.  Am J Pathol. 2008;  173(3) 856-864
    CrossrefPubMedGoogle Scholar
  • 113 Budhu A, Jia H L, Forgues M et al.. Identification of metastasis-related microRNAs in hepatocellular carcinoma.  Hepatology. 2008;  47(3) 897-907
    CrossrefPubMedGoogle Scholar
  • 114 Ji J, Shi J, Budhu A et al.. MicroRNA expression, survival, and response to interferon in liver cancer.  N Engl J Med. 2009;  361(15) 1437-1447
    CrossrefPubMedGoogle Scholar
  • 115 Ji J, Yamashita T, Budhu A et al.. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells.  Hepatology. 2009;  50(2) 472-480
    CrossrefPubMedGoogle Scholar
  • 116 Ura S, Honda M, Yamashita T et al.. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma.  Hepatology. 2009;  49(4) 1098-1112
    CrossrefPubMedGoogle Scholar
  • 117 Huang X H, Wang Q, Chen J S et al.. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated.  Hepatol Res. 2009;  39(8) 786-794
    CrossrefPubMedGoogle Scholar
  • 118 Su H, Yang J R, Xu T et al.. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity.  Cancer Res. 2009;  69(3) 1135-1142
    CrossrefPubMedGoogle Scholar
  • 119 Li S, Fu H, Wang Y et al.. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma.  Hepatology. 2009;  49(4) 1194-1202
    CrossrefPubMedGoogle Scholar
  • 120 Coulouarn C, Factor V M, Andersen J B, Durkin M E, Thorgeirsson S S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties.  Oncogene. 2009;  28(40) 3526-3536
    CrossrefPubMedGoogle Scholar

Jessica Zucman-RossiM.D. Ph.D. 

Inserm U674, 27 rue Juliette Dodu

75010 Paris, France

Email: zucman@cephb.fr

      >